Core Viewpoint - The control of Duori Pharmaceutical has officially changed hands following a significant share transfer, impacting the company's governance structure and future direction [1] Share Transfer Details - Xizang Jiakang Times Technology Development Co., Ltd. and Zhoushan Qingchang Enterprise Management Partnership (Limited Partnership) collectively reduced their holdings by 23,680,000 shares, representing 29.60% of the total share capital [1] - The transfer price was set at 32.064 yuan per share, resulting in a total transaction value of 759 million yuan [1] - Post-transaction, the combined shareholding of the two entities decreased from 65.72% to 36.12% [1] Voting Rights and Control Change - Xizang Jiakang has relinquished voting rights associated with 19.44 million shares, which accounts for 24.30% of the total share capital [1] - The new shareholders, Wang Qingtai, Cui Zihao, and Cao Xiaobing, now hold a combined 29.60% stake and will exert control through board nominations and senior management arrangements [1] - The original actual controller, Deng Yong, is no longer recognized as the company's actual controller following this change [1] Future Plans - The information disclosure obligors have no plans to increase their holdings in the next 12 months but intend to partially reduce their shares through a tender offer [1]
多瑞医药：西藏嘉康时代科技发展有限公司与舟山清畅企业管理合伙企业（有限合伙）持股比例已降至36.12%